Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad, reducing their need for clinic visits. New guidance (PDF) from health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback